ANTIRETROVIRAL ACTIVITY OF HYDROXYUREA ALONE AND IN COMBINATION WITH DDI
ANTIRETROVIRAL ACTIVITY OF HYDROXYUREA ALONE AND IN COMBINATION WITH DDI
批准号:
6415298
负责人:
CAROL S DUKES-HAMILTON
金额:
$29.31万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-12-01 至 2001-11-30
中文摘要
目的:本研究的目的是确定羟基脲在两个剂量下是否安全和耐受性良好,这两个剂量将单独检查和与DDI联合使用,以及DDI和羟基尿素联合使用是否会比作为单一治疗原理的任何一个使用更好的抗病毒效果。脱氧核糖核酸三磷酸(DNTPs)是细胞DNA的构建块,在细胞内从头合成。因此,细胞DNA的合成依赖于核糖核苷酸还原酶(RR),该酶催化所有四种核苷酸以还原的脱氧形式存在。通过干扰dNTPs的浓度可以减少HIV的复制。羟基脲抑制RR活性,从而停止细胞DNA合成,降低HIV逆转录的效率。该活性与核苷逆转录酶抑制剂具有协同作用。体外试验表明,羟基脲和DDI之间的协同作用大于ZDV。方法:这是一项为期24周的I/II期随机、双盲、剂量范围的研究,研究对象为HIV感染者,其CD4淋巴细胞计数在200-500之间。将有两个为期12周的疗程和5个学习臂。将对所有受试者进行药代动力学监测。在第2、4、8、12和24周将获得HIV RNA定量水平、CD4+/CD8+淋巴细胞计数和dATP测量的样本。该研究最初为期12周的部分旨在收集数据,用于进行抗逆转录病毒活性分析。在抗逆转录病毒活性分析中使用的主要比较将是羟基脲+DDI联合疗法和DDI单一疗法之间的比较。第8周的血浆HIV RNA水平将用于这一比较。在第12周结束后,接受联合治疗的受试者将继续接受目前的治疗;而接受DDI单一治疗的受试者将继续接受DDI治疗,并按指定剂量(1:1随机分配)添加羟基脲,即1000 mg qd或1500 mg qd。在第12周,DDI单一治疗组的受试者随机接受低剂量或高剂量羟基尿素+DDI联合治疗,这将在研究开始时发生。因此,所有受试者将在12至24周内接受联合治疗,其中一半接受剂量为1000 mg的羟基尿素,另一半接受剂量为1500 mg的每日1次。在12到24周内,所有研究药物都将是开放标签的,不含安慰剂。将按预定时间间隔进行以下临床和实验室评估。根据新的和正在进行的体征或症状在第4、8、12、18和24周进行有针对性的体检;在第4、12、24周进行体重检查;在第12和24周对有生育潜力的妇女进行Karnofsky状态、尿液镜检和血清β-HCG检测;在第2、4、8、12、18和24周进行CBC、MCV、差别和血小板;电解质、肝功能测试、淀粉酶、碱性磷酸酶和总胆红素。结果和未来计划:研究仍在进行中,治疗组仍处于盲目状态,因此研究结论和意义尚不能讨论。这项研究目前尚未完成,但仍在对患者进行跟踪调查。正在考虑一个更长期的后续阶段。
英文摘要
Purpose: The purpose of this study is to determine whether hydroxyurea is safe and well tolerated at the two doses that will be examined alone and in combination with ddI, and whether there will be a more favorable antiviral effect when ddI and hyroxyurea are used in combination as compared to either one used as monotherapy Rationale Deoxyribonucleotide triphosphates (dNTPs) are the building blocks for cellular DNA and are synthesized de novo within the cell. Therefore, cellular DNA synthesis is dependent on the enzyme ribonucleotide reductase (RR), which catalyzes all four ribonucleotides to the reduced deoxy-form. HIV replication can be decreased by interfering with the concentration of dNTPs. Hydroxyurea inhibits RR activity and thus halts cellular DNA synthesis, and decreases the efficiency of HIV reverse transcription. This activity is synergistic with nucleoside RT inhibitor. In vitro testing shows greater synergy between hydroxyurea and DDI than with ZDV. Methods: This is a 24 week, phase I/II, randomized, double-blind, dose-ranging study in HIV-infected adults, whose CD4 lymphocyte count is between 200-500. There will be two 12-week treatment periods and 5 study arms. Pharmacokinetic monitoring will be performed on all subjects. Specimens for quantitative HIV RNA levels, CD4+/CD8+ lymphocyte counts, and dATP measurements will be obtained on weeks 2, 4, 8, 12 and 24. The initial 12-week portion of the study is designed to gather data that will be used to perform an antiretroviral activity analysis. The principal comparison used in the antiretroviral activity analysis will be between the hydroxyurea + ddI combination therapy arms and the ddI monotherapy arm. The Week 8 plasma HIV RNA levels will be used in this comparison. After the completion of Week 12, subjects on combination therapy will remain on their current therapy; and subjects on ddI monotherapy will remain on ddI and have hydroxyurea added at an assigned dose (1:1 randomization) of 1000 mg qd or 1500 mg qd. Randomization of subjects in the ddI monotherapy arm to low or high dose hydroxyurea + ddI combination therapy at Week 12 will have occurred at study entry. Therefore, all subjects will receive combination therapy during Weeks 12 to 24, with half receiving hydroxyurea at a dose of 1000 mg qd and half receiving hydroxyurea at a dose of 1500 mg qd. During Weeks 12 to 24, all study medication will be open label with no placebos. The following clinical and laboratory evaluations will be performed at scheduled intervals. Targeted physical exam based on new and ongoing signs or symptoms at Weeks 4, 8, 12, 18, and 24; weight at Weeks 4, 12, 24; Karnofsky status, urinalysis with microscopic examination, and serum beta-HCG test for women of child-bearing potential at Weeks12 and 24; CBC with MCV, differential and platelets; electrolytes, liver function tests, amylase, alkaline phosphatase and total bilirubin will be done at Weeks 2, 4, 8, 12, 18 and 24. Results and Future Plans: The study is ongoing and treatment arms remain blinded, therefore study conclusions and significance can not yet be discussed. The study is currently closed to accrual, though patients are continuing to be followed. A longer-term follow-up phase is being contemplated.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RIFAPENTINE FOR RELAPSE AMONG HIV SEROPOSITIVE & SELECTED SERONEGATIVE
-
批准号:6565305
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2001
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
IV OR SQRHIL2 IN HIV INFECTED SUBJECTS ON HAART
-
批准号:6565360
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2001
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
ANTIRETROVIRAL ACTIVITY OF HYDROXYUREA ALONE AND IN COMBINATION WITH DDI
-
批准号:6565357
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2001
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
IV OR SQRHIL2 IN HIV INFECTED SUBJECTS ON HAART
-
批准号:6463063
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2000
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
ANTIRETROVIRAL ACTIVITY OF HYDROXYUREA ALONE AND IN COMBINATION WITH DDI
-
批准号:6503097
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2000
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
RIFAPENTINE FOR RELAPSE AMONG HIV SEROPOSITIVE & SELECTED SERONEGATIVE
-
批准号:6463008
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2000
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
ANTIRETROVIRAL ACTIVITY OF HYDROXYUREA ALONE AND IN COMBINATION WITH DDI
-
批准号:6463060
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2000
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
RIFAPENTINE FOR RELAPSE AMONG HIV SEROPOSITIVE & SELECTED SERONEGATIVE
-
批准号:6415246
-
项目类别:
-
资助金额:$29.31万
-
财政年份:2000
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
RIFAPENTINE FOR RELAPSE AMONG HIV SEROPOSITIVE & SELECTED SERONEGATIVE
-
批准号:6503045
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2000
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
IV OR SQRHIL2 IN HIV INFECTED SUBJECTS ON HAART
-
批准号:6503100
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2000
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
IV OR SQRHIL2 IN HIV INFECTED SUBJECTS ON HAART
-
批准号:6415301
-
项目类别:
-
资助金额:$29.31万
-
财政年份:2000
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
RIFAPENTINE FOR RELAPSE AMONG HIV SEROPOSITIVE & SELECTED SERONEGATIVE
-
批准号:6302909
-
项目类别:
-
资助金额:$4.09万
-
财政年份:1999
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
ANTIRETROVIRAL ACTIVITY OF HYDROXYUREA ALONE AND IN COMBINATION WITH DDI
-
批准号:6112780
-
项目类别:
-
资助金额:$4.09万
-
财政年份:1998
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
IV OR SQRHIL2 IN HIV INFECTED SUBJECTS ON HAART
-
批准号:6112784
-
项目类别:
-
资助金额:$4.09万
-
财政年份:1998
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
RIFAPENTINE FOR RELAPSE AMONG HIV SEROPOSITIVE & SELECTED SERONEGATIVE
-
批准号:6263407
-
项目类别:
-
资助金额:$4.09万
-
财政年份:1998
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
ANTIRETROVIRAL ACTIVITY OF HYDROXYUREA ALONE AND IN COMBINATION WITH DDI
-
批准号:6274014
-
项目类别:
-
资助金额:$2.88万
-
财政年份:1997
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
IV OR SQRHIL2 IN HIV INFECTED SUBJECTS ON HAART
-
批准号:6274018
-
项目类别:
-
资助金额:$2.88万
-
财政年份:1997
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
PHASE I STUDY OF TESTODERMR-TTS IN HYPOGONADAL MALES WITH/WITHOUT AIDS
-
批准号:6243971
-
项目类别:
-
资助金额:$3.24万
-
财政年份:1975
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
ANTIRETROVIRAL ACTIVITY OF HYDROXYUREA ALONE AND IN COMBINATION WITH DDI
-
批准号:6302961
-
项目类别:
-
资助金额:$4.09万
-
财政年份:--
-
负责人:CAROL S DUKES-HAMILTON
-
依托单位:
海外基金